OECD-407 Driven 28-day-repeated-dose non-clinical safety evaluation of Tinospora cordifolia (Giloy) stem aqueous extract in Sprague-Dawley rats under GLP compliance

Balkrishna, Acharya; Haldar, Swati; Varshney, Anurag

doi:10.3389/fphar.2023.1095083

Cited by 3 publications

(2 citation statements)

References 47 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, increasing the dose of TCE to achieve a higher DEM AUC /DEX AUC should be thoroughly investigated to optimize its utility as a complementary therapy. Nonetheless, the No-Observed-Adverse-Effect-Level (NOAEL) of TCE is reported to be 1000 mg/kg/day and there is scope for its application at lower doses . Moreover, TCE has been demonstrated to improve the cognitive functions related to AD in a preclinical model .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Tinospora cordifolia Extract Enhances Dextromethorphan Bioavailability: Implications for Alzheimer’s Disease

Majhi,

Sayyad,

Gaur

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Tinospora cordifolia (Willd.) Miers (Menispermaceae) is a traditional rejuvenator and a conventional medicine used to manage oxidative stress-related diseases, including those associated with the central nervous system. Decreased dextromethorphan (DEM) metabolism is necessary for high bioavailability and application against Alzheimer’s disease (AD). Since T. cordifolia stem extract (TCE) can potentially inhibit several metabolic enzymes, it can also enhance dextromethorphan bioavailability. This study investigates the potential of TCE to improve DEM’s bioavailability and efficacy for the management of AD. In silico analysis was carried out to find the inhibition potential of phytocomponents of T. cordifolia for CYP2D6 and CYP3A4. The LC-MS method was revalidated for the analysis of DEM and metabolite dextrorphan (DEX) in the presence of quinidine (QN). The ratio of DEM to DEX was estimated with varying doses of TCE following pharmacokinetic analysis. Network pharmacology analysis was carried out to understand the complementary potential of phytocomponents. This was further validated in the scopolamine-induced dementia model through behavioral and histopathological analyses. TCE (100 mg/kg) for 14 days increased the DEM to DEX ratio by 2.8-fold compared to QN treatment. While T max was comparable to that of QN treatment at this dose (100 mg/kg) of TCE, it increased significantly at the higher dose (400 mg/kg) of TCE pretreatment. All other pharmacokinetic parameters were also enhanced at this dose with a 4.7-fold increase in DEM/DEX compared with QN. Network pharmacology analysis indicated the ability of TCE to target multiple factors associated with AD. Furthermore, it improved spatial memory and reduced hyperactivity in rodents better than the combination of QN and DEM.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Nonetheless, the No-Observed-Adverse-Effect-Level (NOAEL) of TCE is reported to be 1000 mg/kg/day and there is scope for its application at lower doses. 40 Moreover, TCE has been demonstrated to improve the cognitive functions related to AD in a preclinical model. 41 However, this is yet to be clinically validated.…”

Section: Resultsmentioning

confidence: 99%

Tinospora cordifolia Extract Enhances Dextromethorphan Bioavailability: Implications for Alzheimer’s Disease

Majhi,

Sayyad,

Gaur

et al. 2024

ACS Omega

View full text Add to dashboard Cite

show abstract

Efficacy of antidiabetic plants available in Himachal Pradesh in management of diabetes: a comprehensive review

Gupta,

Bano,

Kimta

et al. 2024

Phytochem Rev

View full text Add to dashboard Cite

Exploration of medicinal plants as potential therapeutics against COVID-19: molecular insights and drug development prospects with other significant medicinal information a retrospective exposition

Dilip Bhandare

2024

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives The study aims to explore the potential of medicinal plants and their phytoconstituents as effective inhibitors of the coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus. The focus is on investigating specific medicinal plants known for their pharmacological properties, such as: antioxidant, anti-inflammatory, and immunomodulatory effects, to determine their viability in developing COVID-19 treatments. Materials and methods This study involves a comprehensive study of medicinal plants, including: Withania somnifera (Ashwagandha) and Ocimum sanctum (Holy Basil), known for their beneficial health effects. Molecular docking studies were conducted to assess the interactions between phytoconstituents from these plants and SARS-CoV-2 proteins. The compounds’ drug-like characteristics and safety profiles were also evaluated to determine their potential as therapeutic agents. Results The molecular docking studies revealed that the phytoconstituents from the studied medicinal plants exhibit favourable interactions with SARS-CoV-2 proteins, suggesting their potential as therapeutic targets. These compounds demonstrated promising drug-like characteristics and safety profiles, indicating their suitability for further development as COVID-19-fighting medications. Discussion The results indicate that medicinal plants and their bioactive substances hold significant potential for developing therapies against COVID-19. The ability of these organic substances to interact with key viral proteins and provide various therapeutic benefits highlights their potential as multi-functional treatment options. However, further research is necessary to confirm these findings and to understand the full scope of their therapeutic efficacy and safety in clinical settings. Conclusions Medicinal plants and their phyto-constituents represent a promising avenue for developing effective treatments for COVID-19. The favourable interactions with SARS-CoV-2 proteins and the promising drug-like characteristics observed in this study suggest that these natural compounds could be integral in the fight against the COVID-19 pandemic. Further research and clinical trials are essential to fully validating their potential and translating these findings into practical medical applications.

show abstract

OECD-407 Driven 28-day-repeated-dose non-clinical safety evaluation of Tinospora cordifolia (Giloy) stem aqueous extract in Sprague-Dawley rats under GLP compliance

Cited by 3 publications

References 47 publications

Tinospora cordifolia Extract Enhances Dextromethorphan Bioavailability: Implications for Alzheimer’s Disease

Tinospora cordifolia Extract Enhances Dextromethorphan Bioavailability: Implications for Alzheimer’s Disease

Efficacy of antidiabetic plants available in Himachal Pradesh in management of diabetes: a comprehensive review

Exploration of medicinal plants as potential therapeutics against COVID-19: molecular insights and drug development prospects with other significant medicinal information a retrospective exposition

Contact Info

Product

Resources

About